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Hassan Vahidnezhad1,2,4, Leila Youssefian1,3,4 and Jouni Uitto1A number of critical signaling pathways are required
for homeostatic regulation of cell survival, differenti-
ation, and proliferation during organogenesis. One of
them is the PI3K-AKT-mTOR pathway consisting of a
cascade of inhibitor/activator molecules. Recently, a
number of heritable diseases with skin involvement,
manifesting particularly with tissue overgrowth, have
been shown to result from mutations in the genes
in the PI3K-AKT-mTOR and interacting intracellular
pathways. Many of these conditions represent an
overlapping spectrum of phenotypic manifestations
forming a basis for novel, unifying classifications.
Identification of the mutant genes and specific mu-
tations in these patients has implications for di-
agnostics and genetic counseling and provides a
rational basis for the development of novel treatment
modalities for this currently intractable group of
disorders.
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Coordinated cell survival, differentiation, and proliferation are
critical for tissue development and growth during organo-
genesis. There are a number of factors that contribute to these
complex processes in multicellular organisms, and alterations
in such critical pathways can be embryonically lethal or may
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tion during development is the PI3K-AKT-mTOR pathway
(Figure 1; Laplante and Sabatini, 2012; Manning and Cantley,
2007; Vanhaesebroeck et al., 2012). This complex intracel-
lular pathway entails phosphatidylinositol-3 kinase (PI3K),
which is activated in response to cell surface tyrosine kinase
receptor-ligand binding, and subsequently converts phos-
phatidylinositol (4, 5)-bisphosphate (PIP2) through phosphor-
ylation to phosphatidylinositol (3, 4, 5)-triphosphate (PIP3;
Figure 1; Hawkins et al., 1992; Ruderman et al., 1990;
Whitman et al., 1988). The conversion of PIP2 to PIP3 can
be reversed by PTEN, which therefore serves as a negative
regulator of PI3K activity (Maehama and Dixon, 1998; Myers
et al., 1998).
PIP3 serves as a plasma membrane docking site for AKT, a
serine/threonine kinase, which, upon phosphorylation by
PKD1 and mTOR2 complex (mTORC2), is released to the
cytoplasm and inhibits tuberous sclerosis protein complex
(TSC1/TSC2; Figure 1). The TSC1/2 complex serves as an
inhibitor of mTOR1, a large, serine/threonine protein kinase
designated as mammalian (or mechanistic) target of rapa-
mycin, a bacterial toxin that inactivates the kinase and is used
clinically as both an immunosuppressant and anticancer drug
(Brown et al., 1994; Burgering and Coffer, 1995; Franke et al.,
1995; Inoki et al., 2002; Manning et al., 2002; Potter et al.,
2002; Sarbassov et al., 2005; Stephens et al., 1998; Stokoe
et al., 1997). mTOR1 is an active protein kinase when
bound by a complex of Rheb and GTP, whereas it is inactive
when complexed with Rheb and GDP (Figure 1). Thus,
mTOR1 is inactivated by hydrolysis of Rheb-bound GTP to
GDP accelerated by active TSCl/TSC2 (Garami et al., 2003;
Inoki et al., 2003a; Tee et al., 2003; Zhang et al., 2003).
In addition, TSCl/TSC2 can be activated by AMP kinase and
by REDD, a hypoxia-induced tumor suppressor, thus adding
to the complexity of regulation of the PI3K-AKT-mTOR
signaling pathway (Brugarolas et al., 2004; Inoki et al.,
2003b).
Another critical intracellular signaling pathway partici-
pating in the regulation of cell growth involves RAS, which is
activated by complexing with GTP. The conversion of GDP to
GTP is inhibited by neurofibromatosis type 1 (NF1), which,
when mutated, leads to neurofibromatosis type 1. Down-
stream from activated RAS are RAF and MEK, resulting in the
activation of MAP kinase (Shaw and Cantley, 2006). Active
MAP kinase can inhibit the TSC1/TSC2 complex by specif-
ically phosphorylating TSC2, or indirectly through activation
of RSK, and thereby activating mTOR1 (Figure 1; Ballif et al.,estigative Dermatology. www.jidonline.org 15
Figure 1. The complexity of the PI3K-AKT-mTOR and interacting signaling pathways, with associated heritable diseases with skin involvement as a result of
mutations in the corresponding genes. The key molecules in the pathway are highlighted by colored overlay. AMPK, AMP kinase; MAPK, MAP kinase; NF1,
neurofibromatosis type 1; VEGF, vascular endothelial growth factor.
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162005; Ma et al., 2005). Thus, both the PI3K-AKT and
RASeMAP kinase signaling pathways converge on the
mTOR1 complex to regulate cell growth (Shaw and Cantley,
2006).
Activated mTOR1 in the Rheb-GTP complex phosphory-
lates and inactivates downstream targets such as 4E-BP1,
causing it to release eIF4E, which stimulates translation
initiation. It also phosphorylates and activates S6 kinase,
which in turn phosphorylates ribosomal proteins, again
stimulating translation (Ma and Blenis, 2009). Activated
mTOR1 also activates necessary transcription factors for RNA
polymerases I and III, leading to the synthesis and assembly
of ribosomes, tRNAs, and translation factors (Kantidakis et al.,
2010; Mayer et al., 2004). In the absence of mTOR activity,
all of these processes are shut down. Thus, the mTOR1
complex has a critical role in regulating proliferation, growth,
and survival of cells, and consequently in controlling
organogenesis. mTOR1 can also activate hypoxia-induced
factor 1-a (HIF1-a), an inducer of vascular endothelial
growth factor (VEGF) and angiogenesis (Figure 1; Brugarolas
et al., 2003; Hudson et al., 2002). HIF1-a is inhibited by
prolyl hydroxylase encoded by the PHD gene. Specifically,
under normoxic conditions, the hydroxylated form of HIF1-a
binds the von Hipple-Lindau protein, which catalyzes
polyubiquitylation and proteosomal degradation of HIF1-a.
In contrast, under hypoxic conditions, unhydroxylated HIF1-
a, together with HIF1-b, binds the promoter region of genes,
such as VEGF, enhancing transcription and promoting
angiogenesis. Besides hypoxic conditions, prolyl hydroxylase
is inhibited by radical oxygen species, the formation of which
is influenced by fumarate hydratase (Majmundar et al., 2010;Journal of Investigative Dermatology (2016), Volume 136Sabharwal and Schumacker, 2014). Mutations in the corre-
sponding gene, FH, are associated with the development of
leiomyomatosis and type 2 papillary renal cell cancer
(Figure 1; Tomlinson et al., 2002). Collectively, there is an
intracellular network of signaling pathways, which contribute
to the regulated morphogenesis and tissue growth. Mutations
in the corresponding genes can result in a spectrum of
phenotypically overlapping diseases, many of which are
characterized by tissue overgrowth (Table 1).
MOLECULAR BASIS OF TISSUE OVERGROWTH
SYNDROMES
The interest in the PI3K-AKT-mTOR pathway has been
recently heightened by identification of mutations in the
corresponding genes in diseases characterized by tissue
overgrowth (Figure 2 and Table 1). The prototype of such
conditions is the Proteus syndrome (PS) characterized by
postnatal asymmetric overgrowth of tissues usually affecting
the lower extremities, such as in the form of development of
cerebriform connective tissue nevi (Beachkofsky et al.,
2010). Most patients with PS harbor somatic mutations in
the AKT1 gene, and all cases with mutations in this gene
display the same recurrent gain-of-function missense mu-
tation, p.E17K, in exon 1, which is present only in the
affected overgrowth tissue in a mosaic pattern but not in
normal tissue or in blood cells (Lindhurst et al., 2011).
However, patientswith PS-like findingshavealsobeen reported
to have loss-of-functionmutations, some of them being germline
mutations with very severe phenotype, in the PTEN gene (Marsh
et al., 2008; Pritchard et al., 2013; Salo-Mullen et al., 2014;
Schmid et al., 2014). In addition, both somatic and germline
Table 1. Mendelian disorders related to PI3K-AKT-mTOR pathway
Gene Protein/function
Mode of
inheritance/action Syndromes1 Clinical characteristics Publications
PIK3CA PI3-Kinase subunit a (p110-a),
the catalytic subunit of PI3K,
which adds a phosphate to
phosphatidylinositol-4,5-
biphosphate (PIP2) to form
phosphatidylinositol-3,4,5-
triphosphate (PIP3)
Somatic and mosaic;
gain of function
PIK3CA-related
overgrowth spectrum
(PROS) (see Table 2)
Multiple organ involvement or
congenital tissue-limited
asymmetrical overgrowth syndrome
See Table 2
Germline; gain of
function
Cowden-like syndrome
(no. 5)
Benign and malignant neoplasias as
well as cerebral overgrowth and
neurodevelopmental abnormalities
Orloff et al.,
2013
PIK3R2 p85b regulatory subunit of the
PI3K
Germline; gain of
function
Megalencephaly-
polymicrogyria-
polydactyly-
hydrocephalus
syndrome 1 (MPHH1)
In utero onset; megalencephaly,
polymicrogyria, postaxial
polydactyly in half of the reported
cases
Riviere et al.,
2012
PTEN A lipid phosphatase which
dephosphorylates PIP3 to PIP2,
thereby inhibiting AKT
Germline;
haploinsufficiency, loss
of function
PTEN Hamartoma
Tumor syndrome
(PHTS) which includes
Cowden syndrome 1
(CS1), Bannayan-Riley-
Ruvalcaba syndrome
(BRRS), PTEN-related
Proteus syndrome (PS)
Benign and malignant neoplasias;
cerebral overgrowth and
neurodevelopmental abnormalities,
asymmetrical bone and soft tissue
overgrowth
Liaw et al.,
1997; Marsh
et al., 1997
Somatic and mosaic;
haplo-insufficiency,
loss of function
Pritchard et al.,
2013; Salo-
Mullen et al.,
2014
AKT1 (PKB) Protein kinase B (PKB)-alpha, a
serine/threonine protein kinase
Somatic and mosaic;
gain of function
Proteus syndrome Overgrowth, usually affecting lower
extremeties
Lindhurst et al.,
2011
Germline; gain of
function
Cowden-like syndrome
(no. 6)
Benign and malignant neoplasias as
well as cerebral overgrowth and
neurodevelopmental abnormalities
Orloff et al.,
2013
AKT2 (PKBB) PKB-Beta, a serine/threonine
protein kinase
Germline or very early
somatic; gain of
function
Hypoinsulinemic
hypoglycemia with
hemihypertrophy
Recurrent and severe fasting
hypoglycemia, reduced
consciousness and seizures;
asymmetrical growth
Hussain et al.,
2011
AKT3
(PKBG)
PKB-Gamma, a serine/threonine
protein kinase
Germline; gain of
function
Megalencephaly-
polymicrogyria-
polydactyly-
hydrocephalus
syndrome 2 (MPPH2)
In utero onset; megalencephaly,
polymicrogyria, postaxial
polydactyly in half of the reported
cases
Riviere et al.,
2012
TSC1/TSC2 Hamartin/Tuberin, inhibitors of
mTOR (mechanistic target of
rapamycin) serine/threonine
protein kinase
Dominant; haplo-
insufficiency, loss of
function
Tuberous sclerosis Hypomelanotic macules, facial
angiofibromas, shagreen patches,
fibrous facial plaques, ungual and
subungual fibromas, cortical tubers,
subependymal nodules and
subependymal giant cell
astrocytomas, seizures, intellectual
disability/developmental delay
Povey et al.,
1994
NF1 Neurofibromin, negative
regulator of the Ras signal
transduction pathway
Dominant; haplo-
insufficiency, loss of
function
von Recklinghausen
neurofibromatosis
(neurofibromatosis
type I)
Cafe´-au-lait spots, axillary or groin
freckling, Lisch nodules,
neurofibromas, optic pathway
gliomas, bone dysplasia, scoliosis,
learning disabilities and epilepsy
Wallace et al.,
1990
MTOR mTOR, a serine/threonine protein
kinase
Sporadic, dominant;
gain of function
Focal cortical dysplasia
type II
Malformation of the cerebral cortex
characterized by dysmorphic
neurons, dyslamination and
medically refractory epilepsy
Lim et al., 2015
LKB1
(STK11)
Serine/threonine kinase Dominant; haplo-
insufficiency, loss of
function
Peutz-Jeghers
syndrome
Melanocytic macules of the lips,
multiple gastrointestinal
hamartomatous polyps, and an
increased risk for various neoplasms,
including gastrointestinal cancer
Jenne et al.,
1998
FLCN Folliculin Dominant;
haploinsufficiency, loss
of function
Birt-Hogg-Dube´
syndrome
Hair follicle hamartomas, kidney
tumors, spontaneous pneumothorax
Nickerson et al.,
2002
REDD
(KRIT1)
KRIT1, ankyrin repeat containing
(CCM1)
Dominant; haplo-
insufficiency, loss of
function
Cerebral cavernous
malformations-1
Hyperkeratotic cutaneous capillary-
venous malformations associated
with cerebral capillary
malformations
Laberge-le
Couteulx et al.,
1999
(continued )
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Table 1. Continued
Gene Protein/function
Mode of
inheritance/action Syndromes1 Clinical characteristics Publications
VHL E3 ubiquitin protein ligase Dominant; haplo-
insufficiency, loss of
function
von Hippel-Lindau
syndrome
Angiomatosis of the retina and
hemangioblastoma of the
cerebellum; pheochromocytoma in
some patients
Latif et al., 1993
FH Fumarate hydratase, (fumarase),
an enzyme of Krebs cycle
Dominant; haplo-
insufficiency, loss of
function
Leiomyomatosis and
renal cell cancer
Inherited uterine fibroids, skin
leiomyomatosis and papillary renal
cell cancer
Alam et al.,
2001
SDHB and
SDHD
Mitochondrial succinate
dehydrogenase: complex II of
electron transfer chain and
enzyme of Krebs cycle
Dominant; haplo-
insufficiency, loss of
function
Cowden-like syndrome
(nos. 2 and 3,
respectively)
Benign and malignant neoplasias as
well as cerebral overgrowth and
neurodevelopmental abnormalities
Ni et al., 2008
Abbreviations: NF1, neurofibromatosis type 1; TSC, tuberous sclerosis protein complex.
1These syndromes demonstrate considerable phenotypic overlap in the spectrum of these multisystem disorders.
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18loss-of-function mutations have been disclosed in the PTEN
gene in patients with the Cowden syndrome characterized
by soft-tissue overgrowth commonly found in the skin and
mucous membranes, but which can also affect the intestine
and other parts of the body (Tan et al., 2011). The patients
with the Cowden syndrome are at risk for developing several
types of cancers, particularly of breast, thyroid, and endo-
metrium (Tan et al., 2012). The development of hamartomas
and increased cancer risk as a result of mutations in the
Cowden syndrome reflects the function of PTEN as a tumor
suppressor protein, and loss-of-function mutations lead
to uncontrolled cell growth and proliferation, resulting
in aberrant tissue growth. Another condition, the
BannayaneRileyeRuvalcaba syndrome with childhood
onset, has overlapping features with the Cowden syndrome
and also harbors mutations in the PTEN gene (Marsh et al.,
1997). On the basis of these similarities, it has been sug-
gested that, rather than being distinct diagnostic conditions,
these diseases belong to the spectrum of the PTEN hamar-
toma syndrome (Lachlan et al., 2007). It should also be noted
that mutations in the SDHB and SDHD genes, which
contribute to the synthesis of succinate dehydrogenase, can
result in the development of the Cowden-like syndrome.
Succinate dehydrogenase, important for cellular energy pro-
duction, controls cell survival and proliferation, and hetero-
zygous inactivating mutations allow uncontrolled cell growth
and proliferation, leading to the formation of hamartomas
and malignant tumors (Ni et al., 2008). Furthermore, some
patients with Cowden-like syndrome have been shown to
harbor alterations in the KLLN gene, which encodes killin, a
putative tumor-suppressor protein. Reduced expression of
killin may result from hypermethylation of KLLN promoter
(Bennett et al., 2010). Collectively, the Cowden-like syn-
drome can result from mutations in several different genes,
and a gene-based classification has been suggested by the
Online Mendelian Inheritance in Man to consist of different
subtypes with similar phenotypic presentations but mutations
in different genes: Cowden syndrome no. 1, PTEN; no.
2, SDHB; no. 3, SDHD; no. 4, KLLN; no. 5, PI3K; and no.
6, AKT1.
Another condition with hamartomatous growth affecting
the skin is the BirteHoggeDube´ syndrome inherited in anJournal of Investigative Dermatology (2016), Volume 136autosomal dominant pattern. Although the signs and symp-
toms are variable, this syndrome is characterized by benign
skin tumors, particularly fibrofolliculomas and trichodisco-
mas, on the face, neck, and upper chest. Affected individuals
can also develop pneumothorax as a result of developing
cysts in the lungs, and there is an elevated risk for both
cancerous and noncancerous tumors in the kidneys (Toro
et al., 2008). BirteHoggeDube´ syndrome is caused by mu-
tations in the FLCN gene, which encodes folliculin, a putative
tumor suppressor that inhibits mTOR2, thus interfering with
phosphorylation and activation of AKT with downstream
consequences on cell growth and proliferation (Nickerson
et al., 2002). In addition, FLCN is activated by AMP kinase
reflecting the cellular ATP/AMP depletion and attesting to
complex molecular genetics of these disorders (Baba et al.,
2006; Hasumi et al., 2009).
Another disorder characterized by hamartomatous polyps
in the gastrointestinal tract and greatly increased risk for
developing certain types of cancers is the PeutzeJeghers
syndrome. Children with this syndrome characteristically
develop lentigines on the lips and inside the mouth, signi-
fying the risk for intestinal involvement (Beggs et al., 2010).
The PeutzeJeghers syndrome is caused by mutations in the
LKB1 gene (also known as STK11), a serine/threonine kinase
(Jenne et al., 1998). This enzyme phosphorylates AMP kinase,
which in turn activates the TSC2/TSC1 complex. As the TSC2/
TSC1 complex is an inhibitor of mTOR1, again, mutations in
the specific gene (LKB1) result in hamartomatous growth
(Shackelford and Shaw, 2009).
The TSC1 and TSC2 genes on chromosomes 9 and 16 code
for hamartin and tuberin proteins, respectively, which in a
complex form act as growth suppressors by inhibiting
mTOR1 (Inoki et al., 2003a; Povey et al., 1994; Tee et al.,
2003). Mutations in either one of these genes cause tuber-
ous sclerosis (TSC), a multisystem genetic disease affecting
the central nervous system and a number of internal organs.
The skin manifestations include ashleaf macules, facial
angiofibromas, shagreen patches, and ungual or subungual
fibromas. TSC has an estimated prevalence in 1:6,000 new-
borns, most commonly as a result of de novo mutations in
either TSC1 or TSC2 gene, but autosomal dominant inheri-
tance has also been documented.
Figure 2. Illustration of the phenotypic variability of syndromes in the PIK3CA-related overgrowth spectrum. Note (a and c) the extensive tissue overgrowth in
a patient with fibroadipose hyperplasia; (b and h) CLOVES syndrome, and (d) macrodactyly in a patient with diagnosis of MCAPeKTS. (f) Note the central
nervous system involvement with cortical dysplasia (left panel, star; and right panel, arrowhead) and lateral ventriculomegaly (arrow, left panel) in the patient
shown in d. (e) Note the hemihypertrophy and vascular lesions in a patient with KTS. (g) Demonstration of the efficacy of topical rapamycin in the treatment of
angiofibromas in a patient with tuberous sclerosis (upper panel, before treatment; lower panel, after 12 weeks of treatment). Panels a and c were reproduced
from Youssefian et al., 2015, and panel g from Haemel et al., 2010, with permissions. Panel b is courtesy of Dr Ariana Kariminejad. CLOVES, congenital
lipomatous overgrowth, vascular malformation, epidermal nevi, and skeletal malformation syndrome; KTS, KlippeleTrenaunay syndrome; MCAP,
megaloencephaly-capillary malformation.
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A new syndrome characterized by Congenital Lipomatous
Overgrowth, Vascular malformation, and Epidermal nevi
(CLOVE syndrome) was described in seven patients in 2007.
Some of these patients had overlapping features with other
overgrowth syndromes, such as PS, but it did not meet the
established criteria for the latter disorder. The patients with
CLOVE syndrome demonstrate progressive enlargement of
bone structures with soft-tissue overgrowth and complex
vascular malformations (Figure 2; Sapp et al., 2007; Gucev
et al., 2008). It was subsequently recognized that skeletal
abnormalities, particularly scoliosis, can be a part of this
syndrome, and, consequently, this constellation is now
known as the CLOVES syndrome (Alomari, 2009).
Another syndrome with overlapping features with CLOVES
is fibroadipose hyperplasia characterized by progressivesegmental overgrowth of subcutaneous, muscular, and adi-
pose tissues (Figure 2a and c). Other features include lipo-
matous infiltration of muscle, progressive deposition of
adipose tissue, and vascular malformations (Lindhurst et al.,
2012; Youssefian et al., 2015). Furthermore, the Klippel-
Trenaunay syndrome, which is characterized by a triad of
cutaneous capillary malformations (port wine stain), bone
and soft-tissue hypertrophy, and venous and lymphatic mal-
formations, has a phenotypic overlap with the CLOVES syn-
drome (Vahidnezhad et al., 2015). Klippel-Trenaunay
syndrome has also been reported to be associated with dig-
ital abnormalities, such as polydactyly, macrodactyly, and
syndactyly (see Figure 2), as well as hemimegalencephaly,
seizures, and developmental delay (Jacob et al., 1998;
Cohen, 2000). Another group of disorders with overlapping
phenotypic features has central nervous system involvement,www.jidonline.org 19
Table 2. PIK3CA-Related Overgrowth Spectrum (PROS)
Type of PROS Clinical Characteristics References
Multiple organs
Klippel-Trenaunay syndrome (KTS) Port-wine stain, soft tissue and bony hypertrophy of the extremities and
varicose veins or venous malformations
Kurek et al., 2012;
Luks et al., 2015;
Vahidnezhad et al.,
2015
Megalencephaly-capillary malformation-polymicrogyria
syndrome (MCAP)
Characterized by megalencephaly (MEG) or hemimegalencephaly
(HMEG), polymicrogyria, cerebellar tonsillar ectopia, ventriculomegaly,
vascular malformation, segmental overgrowth, digital anomalies, variable
connective tissue dysplasia
Riviere et al., 2012
Congenital lipomatous asymmetric overgrowth of the trunk,
lymphatic, capillary, venous, and combined-type vascular
malformations, epidermal nevi, skeletal anomalies (CLOVES)
MEG or HMEG; patchy segmental overgrowth associated with skeletal
anomalies, lipomatosis, vascular malformations, and epidermal nevi
Kurek et al., 2012
Hemihyperplasia multiple lipomatosis (HHML) Moderate abnormalities of asymmetry and overgrowth with subcutaneous
lipomatosis
Keppler-Noreuil
et al., 2014
Fibroadipose hyperplasia (FAH); fibroadipose overgrowth (FAO) Congenital segmental progressive overgrowth of subcutaneous, muscular
and visceral fibroadipose tissue, skeletal overgrowth with preserved
architecture or distorting overgrowth, enlarged peripheral nerves,
cutaneous capillary vascular malformations, testicular or epididymal cysts
and hydroceles
Lindhurst et al.,
2012; Youssefian
et al., 2015
Fibroadipose vascular anomaly (FAVA) Fibrofatty infiltration of muscle, unusual phlebectasia with pain, and
contracture of the affected extremity, ankle dorsiflexion
Alomari et al., 2014;
Luks et al., 2015
Facial infiltrating lipomatosis Hemifacial soft-tissue and skeletal overgrowth, precocious dental
development, macrodontia, hemimacroglossia, and mucosal neuromas
Maclellan et al.,
2014
Tissue limited
Isolated lymphatic malformation (ILM) Congenital dilated lymphatic channels or fluid-filled cysts primarily in the
head and neck region; can be localized, multifocal or diffuse, extending
into the chest, abdomen and limbs
Luks et al., 2015;
Osborn et al., 2015
Type I Macrodactyly (lipofibromatous hamartoma
of nerve)
A discrete congenital anomaly consisting of enlargement of all tissues
localized to the terminal portions of a limb, typically within a “nerve
territory.”
Rios et al., 2013
Muscle hemihyperplasia Congenital and unilateral non-progressive muscle overgrowth of the
upper extremity, without other congenital manifestations
Castiglioni et al.,
2014
Mesenteric lipomatosis Localized fat tissue growth Cohen et al., 2014
Epidermal nevi (EN) Keratinocyte-derived benign acanthotic skin tumors; EN are congenital
lesions or develop early during childhood as localized epidermal
thickening with hyperpigmentation; SK are of late onset but can be
identified by age 50 in 80e100% of healthy individuals
Hafner et al., 2007
Seborrheic keratosis (SK)
Benign lichenoid keratosis (BLK)
Also referred to as lichen planus-like keratoses
Slightly raised grayish-brown or red-brown papules or plaques located
predominantly on the upper trunk and the distal upper extremities of
women in the fifth or sixth decade of life
Groesser et al., 2012
Dysplastic megalencephaly (DMEG) Malformations of cerebral cortex, common cause of intractable pediatric
epilepsy
Jansen et al., 2015
Hemimegalencephaly (HMEG)
Focal Cortical Dysplasia (FCD) type IIa
H Vahidnezhad et al.
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20as for example, the MCAP syndrome (megalencephaly-
capillary malformation), with cutaneous vascular abnormal-
ities. Some of the patients with the MCAP syndrome also
demonstrate segmental overgrowth together with digital ab-
normalities. Thus, there is a phenotypic overlapping spec-
trum among the syndromes characterized by tissue
overgrowth (Clayton-Smith et al., 1997; Moore et al., 1997).
The explanation for the similarities in presentation and
phenotypic overlap is provided by recent demonstrations that
CLOVES, fibroadipose hyperplasia, KlippeleTrenaunay syn-
drome, and MCAP all are allelic and harbor mutations in the
PIK3CA gene (Table 1; Kurek et al., 2012; Lindhurst et al.,
2012; Luks et al., 2015; Mirzaa et al., 2012; Riviere et al.,
2012; Vahidnezhad et al., 2015). This gene encodes the
catalytic 110-kD a subunit of PI3K, and this group of disor-
ders has been designated as the PIK3CA-related overgrowth
spectrum (PROS; Keppler-Noreuil et al., 2015). There areJournal of Investigative Dermatology (2016), Volume 136fewer than 30 distinct mutations in the PIK3CA gene reported
thus far, but 5 of them (p.C420R, pE542K, p.E545K, p.
H1047R, and p.H1047L) account for over 80% of cases with
mutations disclosed in this gene in PROS (Keppler-Noreuil
et al., 2014). As the mutations in the PIK3CA gene are so-
matic and arise at different stages of development and in
different cell types, the spatial and temporal expression of the
mutation and the particular cell type being primarily affected
apparently explain the extent of involvement, the type of
tissue overgrowth, and the phenotypic differences and simi-
larities between these conditions. Thus, rather than being
distinct genetic entities, these syndromes appear to be in the
spectrum belonging to the PROS (Table 2; Biesecker and
Spinner, 2013).
Although patients with PROS frequently demonstrate
multiorgan involvement, mutations in the PIK3CA gene have
also been demonstrated in a few conditions limited to the
H Vahidnezhad et al.
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benign lichenoid keratosis. In the reported cases, the muta-
tion results in replacement of a specific glutamic acid residue
either at position 542 or 545 (E542 or E545) by another
amino acid, such as glycine, lysine, or arginine (Groesser et
al., 2012; Hafner et al., 2007). In addition, some patients
with tissue overgrowth have manifestations predominantly in
the central nervous system. One example is cerebral
cavernous malformations because of mutations in the REDD
gene, a regulator of TSC1/TSC2 complex activity (Alam et al.,
2001; Laberge-le Couteulx et al., 1999). Finally, the
PI3K-AKT-mTOR signaling pathway is frequently dysregu-
lated in various malignancies. Specifically, PIK3CAmutations
have been detected in a variety of common solid tumors,
prompting ongoing development of specific PI3K, AKT, and
mTOR complex inhibitors (Campbell et al., 2004; Samuels
et al., 2004).
CLINICAL IMPLICATIONS
Identification of specific mutations in the individuals affected
with various overgrowth syndromes has potential diagnostic
and therapeutic implications. First, demonstration of muta-
tions in some of these patients in mosaic pattern, as reflected
by the finding that they reside only in the overgrowth tissue
and not in normal-appearing skin or in the blood, has im-
plications for genetic counseling of the risk of an affected
individual having an affected child. Specifically, demonstra-
tion that the mutation is somatic markedly reduces the risk for
recurrence in the offspring of an affected individual, as
compared with those conditions with germline mutations,
either autosomal dominant or autosomal recessive.
Second, identification of specific genes allows consider-
ation of treatment options for these conditions. Specifically,
rapamycin, an inhibitor of mTOR activity, has been shown to
reduce cell growth and proliferation, and it could halt the
progressive overgrowth of tissues. In this context, rapamycin
and other mTOR inhibitors, such as everolimus, are in clin-
ical trials to treat patients with malignancies, and early at-
tempts to treat patients with PROS are also under way. In fact,
rapamycin has been used for the treatment of patients with a
germline PTEN mutation in severe PTEN hamartoma syn-
drome (Fogel et al., 2015; Marsh et al., 2008; Schmid et al.,
2014). In one case, treatment with rapamycin for 14 months
resulted in a marked reduction in soft-tissue masses (Marsh
et al., 2008), and in another case an improvement in the
patient’s clinical status was noted (Schmid et al., 2014). It is
also of interest that topical application of rapamycin for the
treatment of facial adenoma sebaceum in patients with tu-
berous sclerosis has been shown to result in marked
improvement in the appearance of some of these patients
(Figure 2g; DeKlotz et al., 2011; Fogel et al., 2015; Haemel et
al., 2010; Tanaka et al., 2013). In addition to mTOR, other
upstream components of this signaling pathway can serve as
targets of pharmacologic inhibition. Specifically, a number of
either Pan-PI3K inhibitors or selective inhibitors of the sub-
units (PI3Ka and PI3Kd) of this complex have been devel-
oped. In fact, the US Food and Drug Administration approved
in 2014 the first-in-class PI3K inhibitor (Idelalisib, Gilead
Pharmaceuticals, Foster City, CA), which targets the p110d
subunit of PI3K, in combination with rituximab, for thetreatment of chronic lymphocytic leukemia, and clinical tri-
als for Hodgkin’s disease are under way. Over a dozen of
other PI3K inhibitors, with varying specificities, are under
development (Ali et al., 2014; Garber, 2014). Similarly, Pan-
AKT inhibitors or those selective for AKT1 or AKT2 have been
identified. The clinical utility of these inhibitors is being
tested in early-stage clinical trials, and their usefulness for the
treatment of tissue overgrowth syndromes, such as PROS, can
be tested in the future (Janku et al., 2014).
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